TY - JOUR
T1 - Monoclonal antibody directed to human T-cell malignancy antigen
AU - Minegishi, Masayoshi
AU - Tsuchiya, Shigeru
AU - Minegishi, Naoko
AU - Yoshie, Osamu
AU - Konno, Tasuke
N1 - Funding Information:
THE DEVELOPMENT of monoclonal antibodies which detect human leukemia-associated cell surface antigens can provide useful tools for clinical diagnosis of leukemias and for purging leukemic cells in vitro from patients' bone marrow cells prior to autologous bone marrow transplantation. One of the most well-known human leukemia-associated cell surface antigens is common acute lymphoblastic leukemia anti- * This work was supported in part by a Research Grant from the Ministry of Education, Science and Culture, Japan.
PY - 1989
Y1 - 1989
N2 - A murine monoclonal antibody (B2D) against a cultured pre-T acute lymphoblastic leukemia (ALL) cell line THP-6 has been produced. The antibody reacted with seven out of eight cultured T-ALL cell lines and with leukemic cells from three out of four T-ALL/lymphoma patients. The antibody did not react with normal T and B lymphocytes, monocytes, granulocytes, platelets, erythrocytes, bone marrow lymphoid-like precursor cells, thymocytes and other acute and chronic leukemic cells of non-T cell origin. Furthermore, B2D did not react with phytohemagglutinin-activated T cells nor with concanavalin A-activated T cells. The molecules immunoprecipitated with B2D had molecular weights of 50-55 kD. Thus, B2D seems to be highly specific for T-cell malignancies. These results show that B2D defines one of human leukemia antigens which are expressed on the cell surface of T-ALL cells. Monoclonal antibody B2D may be useful for the subclassification of T-ALL cells and has therapeutic potential for a certain type of T-ALL.
AB - A murine monoclonal antibody (B2D) against a cultured pre-T acute lymphoblastic leukemia (ALL) cell line THP-6 has been produced. The antibody reacted with seven out of eight cultured T-ALL cell lines and with leukemic cells from three out of four T-ALL/lymphoma patients. The antibody did not react with normal T and B lymphocytes, monocytes, granulocytes, platelets, erythrocytes, bone marrow lymphoid-like precursor cells, thymocytes and other acute and chronic leukemic cells of non-T cell origin. Furthermore, B2D did not react with phytohemagglutinin-activated T cells nor with concanavalin A-activated T cells. The molecules immunoprecipitated with B2D had molecular weights of 50-55 kD. Thus, B2D seems to be highly specific for T-cell malignancies. These results show that B2D defines one of human leukemia antigens which are expressed on the cell surface of T-ALL cells. Monoclonal antibody B2D may be useful for the subclassification of T-ALL cells and has therapeutic potential for a certain type of T-ALL.
KW - T-cell malignancy
KW - monoclonal antibody
KW - tumor cell antigen
UR - http://www.scopus.com/inward/record.url?scp=0024552612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024552612&partnerID=8YFLogxK
U2 - 10.1016/0145-2126(89)90030-1
DO - 10.1016/0145-2126(89)90030-1
M3 - Article
C2 - 2783754
AN - SCOPUS:0024552612
VL - 13
SP - 43
EP - 51
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 1
ER -
